Dexcom DXCM recently announced an upcoming nationwide rollout of an AI-driven upgrade to its Stelo platform aimed at ...

Apple Watch now supports glucose monitoring via CGMs like Dexcom G7, while Apple continues long-term work on non-invasive blood sugar tracking.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $27.4 billion by market ...

Investors reacted sharply as Dexcom flagged lower-than-expected 2026 growth, even as the company defended its key glucose monitor and exceeded third-quarter forecasts. Dexcom shares dropped 12% in US ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

Jake Leach [Image courtesy of Dexcom] After more than 100 days in the corner office at CGM maker Dexcom (NSDQ:DXCM), CEO Jake Leach is excited for the company’s future. In July, Leach was tapped to ...

Jake Leach, Dexcom CEO, joins 'Closing Bell Overtime' to talk its 2026 outlook, the impact of GLP-1s, new devices and more. Got a confidential news tip? We want to hear from you. Sign up for free ...